Achaogen, Inc., a late-stage biopharma company developing antibacterials addressing multi-drug resistant (MDR) gram-negative infections, has been awarded a contract valued at up to $18 million from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of C-Scape, a candidate being developed to treat serious bacterial infections. The BARDA contract includes a nine-month base period with committed funding of $12 million and subsequent option periods that, if...